CEO
Sinaptica Therapeutics, Inc
As CEO of Sinaptica, Ken is leading the team to advance their personalized closed-loop neuromodulation therapy for Alzheimer's, which has generated unprecedented Phase 2 data in two randomized controlled published peer-reviewed trials. Sinaptica has FDA Breakthrough status for its novel approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target-- the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company is now preparing to initiate a pivotal study in 2026.
Ken has 20+ years leading and growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development.
At Boston Scientific's $1B neuromod division, he was the global commercial lead for the Cosman RF ablation business. He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications.
Thursday, January 22, 2026
10:30 AM - 11:15 AM PST